Microcap Healthcare Stocks to Watch: STRR, WHSI, MOTS, ATOS, ADMP

January 21, 2022

The following stocks hit our radar when searching for microcap opportunities in the healthcare sector.  This particular segment of the market is ripe for opportunity when considering speculative investments.  Most of the companies are in early trial stages without any revenue, however, what they lack in revenue they make up for in potential and that’s what moves these markets. One nano-cap option on the OTC in this sector, Wearable Health…


Atossa Therapeutics Inc. (NASDAQ:ATOS) Stock In Correction Mode: Now What?

October 25, 2021

Atossa Therapeutics Inc. (NASDAQ: ATOS) fell 4% last week. The company, which is focusing on the discovery and development of innovative drugs in oncology and infectious diseases, released a video last week recognizing Breast Cancer Awareness Month urging women to receive mammograms. Market Action: On Friday, ATOS stock fell 1.77% at $2.7800 with more than 3.40 million shares, compared to its average volume of 6.57 million shares. The stock has…


Atossa Therapeutics (ATOS) Stock Attempts To Bounce Back After The Sell-Off

September 13, 2021

The clinical stage biopharmaceutical firm Atossa Therapeutics (NASDAQ:ATOS) has been in focus among investors in recent times due to its work on both COVID 19 and cancer treatments. In the first half of the year, the Atossa stock had delivered considerable gains to investors but in the past three months, the trend has reversed in a big way and the stock has lost around 50%. However, it is also true…


Atossa Therapeutics Inc (NASDAQ:ATOS) Stock Under Pressure On FDA Setback

August 17, 2021

Atossa Therapeutics Inc (NASDAQ:ATOS) is down 20% in a month. The company announced its Q2 2021 financial results and offered corporate updates on recent development. In Q2, the company received final findings from the open-label Phase II clinical study of oral Endoxifen during the “window of opportunity” between breast cancer diagnosis and surgery. Endoxifen achieved the primary endpoint in the study with a 65.1% reduction of Ki-67, which is a…


Is Atossa Therapeutics (NASDAQ:ATOS) Stock Worth Buying Near $3 Mark?

August 3, 2021

Atossa Therapeutics (NASDAQ:ATOS), a clinical-stage biotech company with its forte in therapeutic treatments in the department of oncology especially of breast cancer, has been on a roller coaster ride recently. Based in Seattle the company gained much of the investors’ attention in the last year especially as it shifted much of its focus to treating Covid-19 as well, is a hot pick of the initial “meme stock” wave. However, once…


Atossa Therapeutics (NASDAQ:ATOS) Stock Falls Below $3: What’s Going On?

July 31, 2021

Clinical-stage biotech company, Atossa Therapeutics (NASDAQ:ATOS) is witnessing some blows being cash strapped and taking desperate measures for getting operating capital. Investors are always look to put money into biotech stocks, considered as hypergrowth plays, with U.S Food and Drug Administration rulings and patents being around the corner. Seattle based company Atossa, specialising in therapeutic treatment of breast cancer, has been on investor’s radar in the last year as it…